Corporate Governance | Regeneron Pharmaceuticals Inc.

Date	Name	Title	Filing	Type	Shares Traded	Price	Total Held
May 16, 2022	MURPHY ANDREW J EVP Research	EVP Research	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	6,457	$648.31	62,013
Aug 15, 2022	MURPHY ANDREW J EVP Research	EVP Research	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	6,487	$634.25	61,983
May 17, 2022	MURPHY ANDREW J EVP Research	EVP Research	Form 4	Open market or private sale of non-derivative or derivative security	59	$655.40	61,954
Aug 16, 2022	MURPHY ANDREW J EVP Research	EVP Research	Form 4	Open market or private sale of non-derivative or derivative security	76	$639.85	61,907
May 17, 2022	MURPHY ANDREW J EVP Research	EVP Research	Form 4	Open market or private sale of non-derivative or derivative security	58	$656.52	61,896
May 17, 2022	MURPHY ANDREW J EVP Research	EVP Research	Form 4	Open market or private sale of non-derivative or derivative security	60	$657.51	61,836
Aug 16, 2022	MURPHY ANDREW J EVP Research	EVP Research	Form 4	Open market or private sale of non-derivative or derivative security	148	$640.91	61,759
Dec 08, 2023	MURPHY ANDREW J EVP Research	EVP Research	Form 4	Grant, award or other acquisition pursuant to Rule 16b-3(d)	3,199	--	61,737
May 17, 2022	MURPHY ANDREW J EVP Research	EVP Research	Form 4	Open market or private sale of non-derivative or derivative security	123	$658.56	61,713
May 17, 2022	MURPHY ANDREW J EVP Research	EVP Research	Form 4	Open market or private sale of non-derivative or derivative security	77	$660.32	61,636

* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.

Investors & Media